The following stocks are the leading risers and fallers on AIM in London on Thursday.
----------
AIM - WINNERS
----------
N4 Pharma PLC, up 11% at 0.83 pence, 12-month range 0.70p-2.50p. The Derbyshire, England-based pharmaceutical company reports an ‘encouraging’ update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. ‘The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle,’ N4 says.
----------
Sareum Holdings PLC, up 8.0% at 40.50p, 12-month range 33.50p-149.00p. The Cambridge, England-based pharmaceutical company completes a single ascending dose portion of a study probing its SDC-1801 programme. ‘Preliminary blinded safety, tolerability and pharmacokinetics data from the trial indicate a favourable profile and support oral dosing of patients once daily. These preliminary results indicate that SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events,’ it says.
----------
AIM - LOSERS
----------
DSW Capital PLC, down 23% at 46.60p, 12-month range 35.60p-81.00p. The financial advisory reports more ‘normalised’ activity, following five successive months to an ‘improving trading performance through to the end of December’. DSW says Network revenue in January was ‘substantially below our expectations’. DSW provides advisory services in areas such as corporate finance and due diligence. It adds: ‘More significantly, in February, we have been advised of both slippage to some previously anticipated deal revenue and, to a lesser extent, deal aborts, which will impact the group’s FY 24 performance.’ It now expects adjusted pretax profit for the year to March 31 in the range of £600,000 to £700,000, lower than its previous £1.1 million to £1.4 million guidance. ‘Given the return to more uncertainty in the broader M&A market, the board is now more cautious for the FY 25 outturn,’ it adds.
----------
Copyright 2024 Alliance News Ltd. All Rights Reserved.
